author_facet Bertino, Erin M.
Confer, Patricia D.
Colonna, Jorge E.
Ross, Patrick
Otterson, Gregory A.
Bertino, Erin M.
Confer, Patricia D.
Colonna, Jorge E.
Ross, Patrick
Otterson, Gregory A.
author Bertino, Erin M.
Confer, Patricia D.
Colonna, Jorge E.
Ross, Patrick
Otterson, Gregory A.
spellingShingle Bertino, Erin M.
Confer, Patricia D.
Colonna, Jorge E.
Ross, Patrick
Otterson, Gregory A.
Cancer
Pulmonary neuroendocrine/carcinoid tumors : A review article
Cancer Research
Oncology
author_sort bertino, erin m.
spelling Bertino, Erin M. Confer, Patricia D. Colonna, Jorge E. Ross, Patrick Otterson, Gregory A. 0008-543X 1097-0142 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/cncr.24498 <jats:title>Abstract</jats:title><jats:p>Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well‐differentiated bronchial neuroendocrine tumors (also called carcinoid tumors) are reported to account for approximately 25% of all neuroendocrine tumors, they represent only 1% to 2% of all lung cancers. The epidemiology, clinical behavior, and treatment of neuroendocrine carcinoid tumors differ significantly from other lung malignancies. In this article, the recent data regarding these tumors were reviewed with attention to the treatment modalities used. Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) pathway have shown encouraging results in early phase trials for advanced carcinoid tumors. Cancer 2009. © 2009 American Cancer Society.</jats:p> A review article Pulmonary neuroendocrine/carcinoid tumors : A review article Cancer
doi_str_mv 10.1002/cncr.24498
facet_avail Online
Free
finc_class_facet Medizin
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbmNyLjI0NDk4
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbmNyLjI0NDk4
institution DE-D275
DE-Bn3
DE-Brt1
DE-D161
DE-Zwi2
DE-Gla1
DE-Zi4
DE-15
DE-Pl11
DE-Rs1
DE-105
DE-14
DE-Ch1
DE-L229
imprint Wiley, 2009
imprint_str_mv Wiley, 2009
issn 0008-543X
1097-0142
issn_str_mv 0008-543X
1097-0142
language English
mega_collection Wiley (CrossRef)
match_str bertino2009pulmonaryneuroendocrinecarcinoidtumorsareviewarticleareviewarticle
publishDateSort 2009
publisher Wiley
recordtype ai
record_format ai
series Cancer
source_id 49
title_sub A review article
title Pulmonary neuroendocrine/carcinoid tumors : A review article
title_unstemmed Pulmonary neuroendocrine/carcinoid tumors : A review article
title_full Pulmonary neuroendocrine/carcinoid tumors : A review article
title_fullStr Pulmonary neuroendocrine/carcinoid tumors : A review article
title_full_unstemmed Pulmonary neuroendocrine/carcinoid tumors : A review article
title_short Pulmonary neuroendocrine/carcinoid tumors : A review article
title_sort pulmonary neuroendocrine/carcinoid tumors : a review article
topic Cancer Research
Oncology
url http://dx.doi.org/10.1002/cncr.24498
publishDate 2009
physical 4434-4441
description <jats:title>Abstract</jats:title><jats:p>Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well‐differentiated bronchial neuroendocrine tumors (also called carcinoid tumors) are reported to account for approximately 25% of all neuroendocrine tumors, they represent only 1% to 2% of all lung cancers. The epidemiology, clinical behavior, and treatment of neuroendocrine carcinoid tumors differ significantly from other lung malignancies. In this article, the recent data regarding these tumors were reviewed with attention to the treatment modalities used. Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) pathway have shown encouraging results in early phase trials for advanced carcinoid tumors. Cancer 2009. © 2009 American Cancer Society.</jats:p>
container_issue 19
container_start_page 4434
container_title Cancer
container_volume 115
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792343977235578889
geogr_code not assigned
last_indexed 2024-03-01T17:00:17.007Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Pulmonary+neuroendocrine%2Fcarcinoid+tumors+%3A+A+review+article&rft.date=2009-10-01&genre=article&issn=1097-0142&volume=115&issue=19&spage=4434&epage=4441&pages=4434-4441&jtitle=Cancer&atitle=Pulmonary+neuroendocrine%2Fcarcinoid+tumors+%3A+A+review+article&aulast=Otterson&aufirst=Gregory+A.&rft_id=info%3Adoi%2F10.1002%2Fcncr.24498&rft.language%5B0%5D=eng
SOLR
_version_ 1792343977235578889
author Bertino, Erin M., Confer, Patricia D., Colonna, Jorge E., Ross, Patrick, Otterson, Gregory A.
author_facet Bertino, Erin M., Confer, Patricia D., Colonna, Jorge E., Ross, Patrick, Otterson, Gregory A., Bertino, Erin M., Confer, Patricia D., Colonna, Jorge E., Ross, Patrick, Otterson, Gregory A.
author_sort bertino, erin m.
container_issue 19
container_start_page 4434
container_title Cancer
container_volume 115
description <jats:title>Abstract</jats:title><jats:p>Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well‐differentiated bronchial neuroendocrine tumors (also called carcinoid tumors) are reported to account for approximately 25% of all neuroendocrine tumors, they represent only 1% to 2% of all lung cancers. The epidemiology, clinical behavior, and treatment of neuroendocrine carcinoid tumors differ significantly from other lung malignancies. In this article, the recent data regarding these tumors were reviewed with attention to the treatment modalities used. Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) pathway have shown encouraging results in early phase trials for advanced carcinoid tumors. Cancer 2009. © 2009 American Cancer Society.</jats:p>
doi_str_mv 10.1002/cncr.24498
facet_avail Online, Free
finc_class_facet Medizin
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jbmNyLjI0NDk4
imprint Wiley, 2009
imprint_str_mv Wiley, 2009
institution DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229
issn 0008-543X, 1097-0142
issn_str_mv 0008-543X, 1097-0142
language English
last_indexed 2024-03-01T17:00:17.007Z
match_str bertino2009pulmonaryneuroendocrinecarcinoidtumorsareviewarticleareviewarticle
mega_collection Wiley (CrossRef)
physical 4434-4441
publishDate 2009
publishDateSort 2009
publisher Wiley
record_format ai
recordtype ai
series Cancer
source_id 49
spelling Bertino, Erin M. Confer, Patricia D. Colonna, Jorge E. Ross, Patrick Otterson, Gregory A. 0008-543X 1097-0142 Wiley Cancer Research Oncology http://dx.doi.org/10.1002/cncr.24498 <jats:title>Abstract</jats:title><jats:p>Neuroendocrine tumors are a unique malignant neoplasm that can arise from the respiratory tree. Although well‐differentiated bronchial neuroendocrine tumors (also called carcinoid tumors) are reported to account for approximately 25% of all neuroendocrine tumors, they represent only 1% to 2% of all lung cancers. The epidemiology, clinical behavior, and treatment of neuroendocrine carcinoid tumors differ significantly from other lung malignancies. In this article, the recent data regarding these tumors were reviewed with attention to the treatment modalities used. Although conventional cytotoxic therapy has not been reported to demonstrate much promise in this entity over the past 4 decades, newer molecular targeted agents including those that targeted angiogenesis and the mammalian target of rapamycin (mTOR) pathway have shown encouraging results in early phase trials for advanced carcinoid tumors. Cancer 2009. © 2009 American Cancer Society.</jats:p> A review article Pulmonary neuroendocrine/carcinoid tumors : A review article Cancer
spellingShingle Bertino, Erin M., Confer, Patricia D., Colonna, Jorge E., Ross, Patrick, Otterson, Gregory A., Cancer, Pulmonary neuroendocrine/carcinoid tumors : A review article, Cancer Research, Oncology
title Pulmonary neuroendocrine/carcinoid tumors : A review article
title_full Pulmonary neuroendocrine/carcinoid tumors : A review article
title_fullStr Pulmonary neuroendocrine/carcinoid tumors : A review article
title_full_unstemmed Pulmonary neuroendocrine/carcinoid tumors : A review article
title_short Pulmonary neuroendocrine/carcinoid tumors : A review article
title_sort pulmonary neuroendocrine/carcinoid tumors : a review article
title_sub A review article
title_unstemmed Pulmonary neuroendocrine/carcinoid tumors : A review article
topic Cancer Research, Oncology
url http://dx.doi.org/10.1002/cncr.24498